Our scientific innovation and knowledge.

At Phoenix Molecular Designs, we are committed to leading the frontiers of biotechnological research, and we take immense pride in sharing our discoveries and advancements with the global scientific community. This dedication is reflected in our collection of scientific posters and abstracts that we have presented at various international forums, symposiums, and conferences. To view the findings, please click on the titles.

 

Dauntless-1: A Phase 2 Clinical Trial to Evaluate PMD-026, a First-in-Class Pan-RSK Inhibitor, Combined with Fulvestrant to Overcome Resistance to CDK4/6 Inhibitors in Advanced or Metastatic HR+/HER2- Breast Cancer

San Antonio Breast Cancer Symposium (SABCS) 2025

Trial in Progress: Dauntless-1 is a Phase 2 Clinical Trial to Evaluate PMD-026, a First-in-Class Pan-RSK Inhibitor, Combined with Fulvestrant to Overcome Resistance to CDK4/6 Inhibitors in Advanced or Metastatic HR+/HER2- Breast Cancer

American Society of Clinical Oncology (ASCO) Annual Meeting 2025

PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models

San Antonio Breast Cancer Symposium (SABCS) 2024

Patient Selection for High RSK2 Expression is Key for Achieving Improved PFS in Metastatic Breast Cancer in the PMD-026 Phase I/Ib Study

San Antonio Breast Cancer Symposium (SABCS) 2023

Abstract PR02: RSK1 targeting impedes oncogenic driver and inflammatory cytokine signaling to attenuate myeloid neoplasms
Oral Poster

American Association for Cancer Research (AACR) MDS/AML Meeting 2023

Roles of Ribosomal S6 Kinases in Acute Leukemia and Normal Hematopoiesis

American Society of Hematology (ASH)
2023

RSK1 Is an Exploitable Dependency in Myeloid Malignancies
Oral Poster included in the Best of ASH as mentioned here.

American Society of Hematology (ASH) 2023

Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies
Oral Poster

American Society of Hematology (ASH) 2022

Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies

American Society of Hematology (ASH)
2022

San Antonio Breast Cancer Symposium (SABCS) 2022

High Levels of RSK2 in Breast Cancer Patients is Associated with Longer PFS in Patients Treated with PMD-026, a First in Class RSK Inhibitor

American Association for Cancer Research (AACR) Annual Meeting 2022

PMD-026, a First in Class Oral RSK inhibitor, Demonstrates Activity Against Hormone Receptor Positive Breast Cancer with Acquired CDK4/6 Inhibitor Resistance

San Antonio Breast Cancer Symposium (SABCS) 2021

First-in-Human Expansion Study of Oral PMD-026 in Metastatic Triple Negative Breast Cancer Patients

American Society of Clinical Oncology (ASCO) Annual Meeting 2021

First-in-human Phase 1/1b Expansion of PMD-026, an Oral RSK Inhibitor, in Patients with Metastatic Triple-Negative Breast Cancer

American Association for Cancer Research (AACR) Annual Meeting 2021

PMD-026, a First in Class Oral RSK inhibitor, Demonstrates Synergy When Combined with Standard of Care in Breast Cancer Tumor Models

First-in-Human Phase 1/1b Multicenter, Open-Label Dose Escalation Study to Assess Safety and Tolerability of PMD-026, a First-in-Class Oral RSK Inhibitor, in Metastatic Breast Cancer Patients

San Antonio Breast Cancer Symposium (SABCS) 2020

San Antonio Breast Cancer Symposium (SABCS) 2019

PMD-026, a First-in-Class Oral p90 Ribosomal S6 Kinase (RSK) Inhibitor for Triple-Negative Breast Cancer (TNBC)